# US 2005/0032879 A1 · Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032879 A1
- Document ID: US20050032879A1
- Status: Published application
- Kind: A1
- Application number: 10/635,443
- Filed: 2003-08-07
- Published: 2005-02-10
- Earliest claimed: 2003-08-07
- Inventors: Temple Okarter; Richard Aiena; Bhudev Sharma
- Web page: https://patentgrep.com/patent/US20050032879A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The use of a beta-blocker and an ACE-inhibitor in combination for the treatment of cardiovascular disorders, including hypertension and congestive heart failure, is provided. In particular, pharmaceutical formulations which use metoprolol tartrate and enalapril maleate in a therapeutically effective combination in a single extended release dosing unit for the treatment of congestive heart failure are disclosed as well as methods of using those formulations, thereby resulting in a decrease in a patient's overall pill burden.

## Claims

### Claim 1

A method of using a beta-blocker and an ACE-inhibitor in combination for the treatment of cardiovascular disorders comprising:
administering to a subject with a cardiovascular disorder a single dosage unit,
said single dosage unit having a therapeutically effective combination of a beta-blocker and an ACE-inhibitor;
repeating said administering step on a periodic schedule.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said ACE-inhibitor is enalapril maleate or pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

The method according to claim 2 wherein said beta-blocker is metoprolol tartrate or pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 3)

The method according to claim 3 wherein said therapeutically effective combination includes about 2.5 mg to about 60 mg of enalapril maleate.

### Claim 5 (depends on 3)

The method according to claim 3 wherein said therapeutically effective combination includes about 20 mg to about 250 mg of metoprolol tartrate.

### Claim 6 (depends on 3)

The method according to claim 3 wherein said therapeutically effective combination is metoprolol tartrate and enalapril maleate in a ratio from 2.5 to 1 to 100 to 1.

### Claim 7 (depends on 6)

The method according to claim 6 wherein said therapeutically effective combination is metoprolol tartrate and enalapril maleate in a ratio from 5 to 1 to 10 to 1.

### Claim 8 (depends on 1)

The method according to claim 1 wherein said single dosage unit is an extended release dosage unit.

### Claim 9 (depends on 1)

The method according to claim 1 wherein said cardiovascular disorder is congestive heart failure.

### Claim 10

A method of using metoprolol tartrate or pharmaceutically acceptable salts thereof and enalapril maleate or pharmaceutically acceptable salts thereof in combination for the treatment of cardiovascular disorders comprising:
administering to a subject with a cardiovascular disorder a single dosage unit having a therapeutically effective combination of metoprolol tartrate or pharmaceutically acceptable salts thereof and enalapril maleate or pharmaceutically acceptable salts thereof;
repeating said administering step on a periodic schedule.

### Claim 11 (depends on 10)

The method according to claim 10 wherein said therapeutically effective combination includes about 2.5 mg to about 60 mg of enalapril maleate.

### Claim 12 (depends on 10)

The method according to claim 10 wherein said therapeutically effective combination of includes about 20 mg to about 250 mg of metoprolol tartrate.

### Claim 13 (depends on 10)

The method according to claim 10 wherein said cardiovascular disorder is congestive heart failure.

### Claim 14 (depends on 10)

The method according to claim 10 wherein said single dosage unit is an extended release dosage unit.

### Claim 15

An extended release dosage unit for use in the treatment of cardiovascular disorders comprising a core section and an outer section;
said core section containing a therapeutically effective combination of metoprolol tartrate or pharmaceutically acceptable salts thereof and enalapril maleate or pharmaceutically acceptable salts thereof;
said outer section comprising a pharmaceutically acceptable dissolvable coating.

### Claim 16 (depends on 15)

The extended release dosage unit according to claim 15 wherein said therapeutically effective combination of metoprolol tartrate and enalapril maleate is from a 2.5 to 1 ratio to a 100 to 1 ratio of metoprolol tartrate to enalapril maleate.

### Claim 17 (depends on 16)

The extended release dosage unit according to claim 16 wherein said therapeutically effective combination of metoprolol tartrate and enalapril maleate is from a 5 to 1 ratio to a 10 to 1 ratio of metoprolol tartrate to enalapril maleate.

### Claim 18 (depends on 15)

The extended release dosage unit according to claim 15 wherein said therapeutically effective combination includes about 2.5 mg to about 60 mg of enalapril maleate.

### Claim 19 (depends on 15)

The extended release dosage unit according to claim 15 wherein said therapeutically effective combination includes about 20 mg to about 250 mg of metoprolol tartrate.

### Claim 20

A method of reducing a patient's pill burden in the treatment of cardiovascular disorders comprising:
reducing the amount of pills a patient with a cardiovascular disorder ingests per dosing period by administering to said patient a therapeutically effective combination of metoprolol tartrate or pharmaceutically acceptable salts thereof and enalapril maleate or pharmaceutically acceptable salts thereof in a single dosage unit; and
repeating said reducing step.

### Claim 21 (depends on 20)

The method according to claim 20 wherein said single dosage unit is an extended release dosage unit.

### Claim 22 (depends on 20)

The method according to claim 20 wherein said therapeutically effective combination of metoprolol tartrate and enalapril maleate is from a 2.5 to 1 ratio to a 100 to 1 ratio of metoprolol tartrate to enalapril maleate.

### Claim 23 (depends on 22)

The method according to claim 22 wherein said therapeutically effective combination of metoprolol tartrate and enalapril maleate is from a 5 to 1 ratio to a 10 to 1 ratio of metoprolol tartrate to enalapril maleate.

### Claim 24 (depends on 20)

The method according to claim 20 wherein said therapeutically effective combination includes about 2.5 mg to about 60 mg of enalapril maleate.

### Claim 25 (depends on 20)

The method according to claim 20 wherein said therapeutically effective combination includes about 20 mg to about 250 mg of metoprolol tartrate.

### Claim 26

A single dosage unit for use in the treatment of cardiovascular disorders comprising a core section and a pharmaceutically acceptable outer section;
said core section containing a plurality of beads with each of said beads having a drug-containing section;
said plurality of beads comprising a first type of beads which contain metoprolol tartrate or pharmaceutically acceptable salts thereof in said drug-containing section and a second type of beads which contain enalapril maleate or pharmaceutically acceptable salts thereof in said drug-containing section;
wherein said first type of beads and said second type of beads of said plurality of beads together form a therapeutically effective combination of metoprolol tartrate and enalapril maleate.

### Claim 27 (depends on 26)

The single dosage unit according to claim 26 wherein at least some of said first type of beads have a drug release coating at least substantially enveloping said drug-containing section of said first type of beads.

### Claim 28 (depends on 26)

The single dosage unit according to claim 26 wherein at least some of said second type of beads have a drug release coating at least substantially enveloping said drug-containing section of said second type of beads.

### Claim 29 (depends on 26)

The single dosage unit according to claim 26 wherein said therapeutically effective combination of metoprolol tartrate and enalapril maleate is from a 2.5 to 1 ratio to a 100 to 1 ratio of metoprolol tartrate to enalapril maleate.

### Claim 30 (depends on 29)

The single dosage unit according to claim 29 wherein said therapeutically effective combination of metoprolol tartrate and enalapril maleate is from a 5 to 1 ratio to a 10 to 1 ratio of metoprolol tartrate to enalapril maleate.

### Claim 31 (depends on 26)

The single dosage unit according to claim 26 wherein said therapeutically effective combination includes about 2.5 mg to about 60 mg of enalapril maleate.

### Claim 32 (depends on 26)

The single dosage unit according to claim 26 wherein said therapeutically effective combination includes about 20 mg to about 250 mg of metoprolol tartrate.

### Claim 33 (depends on 26)

The single dosage unit according to claim 26 wherein said first type of beads further include enalapril maleate in said drug containing section.

### Claim 34 (depends on 26)

The single dosage unit according to claim 26 wherein said second type of beads further include metoprolol tartrate in said drug containing section.

### Claim 35 (depends on 10)

The method according to claim 10 wherein said single dosage unit comprises a core section and a pharmaceutically acceptable outer section;
said core section containing a plurality of beads with each of said beads having a drug-containing section;
said plurality of beads comprising a first type of beads which contain metoprolol tartrate in said drug-containing section and a second type of beads which contain enalapril maleate in said drug-containing section;
wherein said first type of beads and said second type of beads of said plurality of beads together form said therapeutically effective combination of metoprolol tartrate and enalapril maleate.

### Claim 36 (depends on 1)

The method according to claim 1 wherein said single dosage unit is an immediate release dosage unit.
